The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Arbutus Biopharma (ABUS) is a stock that can certainly grab the ...

Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.

Arbutus Biopharma Corp. has $191 million cash giving a runway of less than 3 quarters. ABUS stock has been reporting net losses since 2013; in 2022, the net loss per share was $0.12. It maintains low ...

Tourlite Capital Management, an investment management firm, released its third quarter 2024 investor letter, a copy of which can be downloaded here. Tourlite Fund, LP Founder Class returned 4.5% for ...

Arbutus Biopharma's three-pronged strategy targets cHBV by suppressing HBV DNA, reducing viral antigens, and boosting immune response. Imdusiran (AB-729) shows promise in Phase 2 trials, potentially ...